Titre:
  • Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2)
Auteur:Cadranel, Jacques; Mauguen, Audrey; Faller, Michele; Zalcman, Gérard; Buisine, Marie-Pierre; Westeel, Virginie; Longchampt, Elisabeth; Wislez, Marie; Coudert, Bruno; Daniel, Catherine; Chetaille, Bruno; Michiels, Stefan; Blons, Helene; Solassol, Jerome; De Fraipont, Florence; Foucher, Pascal; Urban, Thierry; Lacroix, Ludovic; Poulot, Virginie; Quoix, Elisabeth; Antoine, Martine; Danton, Guillaume; Morin, Franck; Chouaid, Christos; Pignon, Jean Pierre
Informations sur la publication:Journal of Thoracic Oncology, 7, 10, page (1490-1502)
Statut de publication:Publié, 2012-10
Sujet CREF:Cancérologie
Pneumologie
Mots-clés:Epidermal growth factor mutation
KRAS mutation
Non-small cell lung cancer
Prognostic factor
Prospective cohort
Tyrosine kinase inhibitor treatment
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1556-0864
info:doi/10.1097/JTO.0b013e318265b2b5
info:scp/84866600312
info:pmid/22982650